Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Avacc 3 has significant advantages over existing whooping cough vaccines
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Subscribe To Our Newsletter & Stay Updated
